CLINICAL TRIALS PROFILE FOR ROXICODONE
✉ Email this page to a colleague
All Clinical Trials for ROXICODONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00726830 ↗ | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | Terminated | National Cancer Institute (NCI) | N/A | 2009-03-01 | RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer. |
| NCT00726830 ↗ | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | Terminated | M.D. Anderson Cancer Center | N/A | 2009-03-01 | RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer. |
| NCT00853216 ↗ | Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets | Completed | Mallinckrodt | Phase 1 | 2003-01-01 | The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 30 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fasting conditions. |
| NCT00853320 ↗ | Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets | Completed | Mallinckrodt | Phase 1 | 2003-02-01 | The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 15 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 15 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fasting conditions. |
| NCT00853736 ↗ | Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets | Completed | Mallinckrodt | Phase 1 | 2003-02-01 | The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available oxycodone tablet (Roxicodone™ 30 mg, Roxane Laboratories, Inc.) in a test group of healthy subjects under fed conditions. |
| NCT00978328 ↗ | Oxycodone User Registry (OUR) | Completed | Ortho-McNeil Janssen Scientific Affairs, LLC | 2009-06-01 | The purpose of this study is to describe clinical and demographic characteristics of patients receiving prescription medications containing oxycodone immediate release (OXYRX), to characterize patient and prescriber perceptions of the effectiveness outcomes and tolerability of OXYRX treatment, to describe prescriber decision-making about pain management with a Schedule II opioid and to explore how prescribers identify suspected abuse of pain medications. | |
| NCT01500317 ↗ | Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans | Completed | National Center for Research Resources (NCRR) | Phase 4 | 2011-05-01 | Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is potential for off label use in chronic pain. Tapentadol is a new molecular entity that is structurally similar to tramadol. Tapentadol is a centrally-acting analgesic with a dual mode of action as an agonist at the mu-opioid receptor and as a norepinephrine reuptake inhibitor. These two actions are synergistic in pain relief. While its action reflects aspects of tramadol and morphine, its ability to control pain is more on the order of hydrocodone and oxycodone. Its dual mode of action provides analgesia at similar levels of more potent narcotic analgesics such as hydrocodone, oxycodone, and meperidine with a more tolerable side effect profile. Clinical studies showed that tapentadol effectively relieves moderate to severe pain in various pain care settings. In addition, it was reported to be associated with significantly fewer treatment discontinuations due to a significantly lower incidence of gastrointestinal-related adverse events compared with equivalent doses of oxycodone. The combination of these reduced treatment discontinuation rates and tapentadol efficacy for the relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in pain therapy by increasing patient compliance with their treatment regimen. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROXICODONE
Condition Name
Clinical Trial Locations for ROXICODONE
Trials by Country
Clinical Trial Progress for ROXICODONE
Clinical Trial Phase
Clinical Trial Sponsors for ROXICODONE
Sponsor Name
